REGN — REGENERON PHARMACEUTICALS, INC.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-01-04.
Performance
Technicals
Dividends
Measured signals that fired on REGN
| date | signal | measured base rate |
|---|---|---|
| 2026-08-19 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
| 2026-08-13 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
| 2026-08-03 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-07-28 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-07-23 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-07-06 | Bollinger bandwidth breaks out of its own compression structure | -0.63% over 21 days · t = -2.80 · n = 7,196 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-19 | LAROSA JOSEPH J EVP General Counsel and Secret | Shares withheld for tax | 9.0K | 830.15 | 7.5M |
| 2026-08-19 | LAROSA JOSEPH J EVP General Counsel and Secret | Option exercise | 12.3K | 381.92 | 4.7M |
| 2026-08-18 | Fenimore Christopher R. EVP Finance CFO | Shares withheld for tax | 4.6K | 813.47 | 3.7M |
| 2026-08-18 | Fenimore Christopher R. EVP Finance CFO | Option exercise | 6.3K | 381.92 | 2.4M |
| 2026-08-10 | Zoghbi Huda Y Director | Open-market sale 10b5-1 plan | 800 | 800.00 | 640.0K |
| 2026-08-10 | Guarini Kathryn Director | Open-market sale 10b5-1 plan | 400 | 800.00 | 320.0K |
| 2026-08-10 | Zoghbi Huda Y Director | Option exercise 10b5-1 plan | 800 | 376.69 | 301.4K |
| 2026-08-10 | Guarini Kathryn Director | Option exercise 10b5-1 plan | 400 | 719.37 | 287.7K |
| 2026-07-02 | RYAN ARTHUR F Director | Open-market sale 10b5-1 plan | 200 | 650.15 | 130.0K |
| 2026-05-01 | RYAN ARTHUR F Director | Open-market sale 10b5-1 plan | 24 | 703.46 | 16.9K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| BlackRock, Inc. | 6.9B | 8.9M |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.1B | 6.7M |
| STATE STREET CORP | 3.6B | 4.7M |
| Dodge & Cox | 3.4B | 4.5M |
| JPMORGAN CHASE & CO | 3.2B | 4.3M |
| FRANKLIN RESOURCES INC | 2.1B | 2.7M |
| GEODE CAPITAL MANAGEMENT, LLC | 2.0B | 2.6M |
| Nuveen, LLC | 1.6B | 2.1M |
| LOOMIS SAYLES & CO L P | 1.5B | 1.9M |
| WELLINGTON MANAGEMENT GROUP LLP | 1.4B | 1.8M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| 4 | 2026-08-12 | 2026-08-10 | on EDGAR ↗ |
| 4 | 2026-08-12 | 2026-08-10 | on EDGAR ↗ |
| 144 | 2026-08-10 | — | on EDGAR ↗ |
| 144 | 2026-08-10 | — | on EDGAR ↗ |
| 13F-HR | 2026-08-07 | 2026-06-30 | on EDGAR ↗ |
| 10-Q | 2026-07-30 | 2026-06-30 | on EDGAR ↗ |
| 8-K | 2026-07-30 | 2026-07-30 | on EDGAR ↗ |
| 4 | 2026-07-07 | 2026-07-02 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REGN · 2026-08-21
- REGN Shareholder Alert: September 14, 2026 Lead Plaintiff Deadline in Regeneron Pharmaceuticals Securities Class Action - Contact SueWallSt · 2026-08-20
- Regeneron Pharmaceuticals, Inc. (REGN) Investors: September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit · 2026-08-20
- REGN Stockholders Interested in Leading the Class Action Against Regeneron Pharmaceuticals, Inc. Should Contact Robbins LLP for Information About Recovering Their Losses · 2026-08-20
- REGN Investor Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Notice - Contact Levi & Korsinsky · 2026-08-19
- Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman Sobol Shapiro LLP · 2026-08-18
Others in Healthcare
Ask the AI about REGN
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →